Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Hemolytic Process | NCIT_C40725 | [Any cytolytic process occurring in erythrocytes, resulting in the release of hemoglobin.] |
| DRG1 wt Allele | NCIT_C126990 | [Human DRG1 wild-type allele is located in the vicinity of 22q12.2 and is approximately 129 kb in length. This allele, which encodes developmentally-regulated GTP-binding protein 1, plays a role in both cell growth regulation and GTP binding.] |
| DRG1 Gene | NCIT_C126989 | [This gene is involved in both GTP binding and cell growth regulation.] |
| 22q12.2 | NCIT_C13595 | [A chromosome band present on 22q] |
| Positive Regulation of Cell Differentiation | NCIT_C40738 | [Cell Differentiation Induction involves initiation of progressive and normally irreversible processes whereby restriction of the developmental potential of immature precursor cells results in increasing specialization of cell function and morphology.] |
| Hematopoiesis Induction | NCIT_C40739 | [Hematopoiesis Induction involves initiation of a process of blood formation; more specifically formation of blood cells that are all derived from hematopoietic stem cells.] |
| Percent Predicted Tidal Volume | NCIT_C112387 | [The volume of air moved into and out of the lungs during breathing at rest as a proportion of the predicted normal value. (CDISC)] |
| BET Inhibitor CC-90010 | NCIT_C151951 | [An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor CC-90010 preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.] |
| Percent Predicted Total Lung Capacity | NCIT_C112388 | [The total volume of air in the lungs after maximum inhalation as a proportion of the predicted normal value. (CDISC)] |
| Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01 | NCIT_C151952 | [A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.] |
| Percent Recovered Infinity Observed Normalized by Body Mass Index | NCIT_C112389 | [The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index.] |
| HSP90-targeted SN-38 Conjugate PEN-866 | NCIT_C151953 | [A miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of HSP90-targeted SN-38 conjugate PEN-866, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, PEN-866 preferentially targets, accumulates and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.] |
| Autologous Anti-Muc1/CD33/CD38/CD56/CD123 Gene-engineered CAR-T Cells | NCIT_C151954 | [A preparation of genetically modified autologous T-cells transduced with lentiviral vectors expressing chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) mucin 1 (Muc1; MUC1), cluster of differentiation 33 (CD33), CD38, CD56 and CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-Muc1/CD33/CD38/CD56/CD123 gene-engineered CAR-T cells are directed to and induce selective toxicity in Muc1/CD33/CD38/CD56/CD123-expressing tumor cells. Muc1/CD33/CD38/CD56/CD123 are present on certain tumor cell types and are minimally expressed on normal, healthy cells. Expression of these TAAs are correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules included in the CARs, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.] |
| Percent Predicted Inspiratory Reserve Volume | NCIT_C112383 | [The maximum volume of air a subject can inhale into the lungs after a tidal inhalation as a proportion of the predicted normal value. (CDISC)] |
| Percent Predicted Peak Expiratory Flow | NCIT_C112384 | [The maximal flow achieved during the maximally forced expiration initiated at maximum inhalation as a proportion of the predicted normal value. (CDISC)] |
| Negative Regulation of Myeloid Cell Apoptotic Process | NCIT_C40732 | [Any process that decreases the frequency, rate or extent of apoptosis in neutrophils, eosinophils or basophils.] |
| Myeloid Cell Apoptotic Process | NCIT_C40720 | [Any apoptotic process occurring in a neutrophil, eosinophil or basophil.] |
| Percent Predicted Residual Volume | NCIT_C112385 | [The volume of air remaining in the lungs after maximum exhalation as a proportion of the predicted normal value. (CDISC)] |
| Percent Predicted Slow Vital Capacity | NCIT_C112386 | [The maximum volume of air that can be exhaled after slow maximum inhalation as a proportion of the predicted normal value. (CDISC)] |
| Supradiaphragmatic | NCIT_C151950 | [Located or performed from above the diaphragm.] |